CD38, an NAD+‐dependent ectoenzyme that is implicated in inflammation and NAD+ degradation and has been hypothesized to be a link between NAD+ metabolism and inflammatory response in COVID‐19 (Zeidler et al., 2022) was markedly upregulated in both RT‐qPCR and RNAseq analyses of COVID‐19 subjects as were NMNAT isoforms and NAMPT, both important enzymes in the NAD+ salvage pathway (Garten et al., 2015). This evidence concerns the gene CD38 and COVID-19.